124 related articles for article (PubMed ID: 21217775)
1. PAX5-PML acts as a dual dominant-negative form of both PAX5 and PML.
Kurahashi S; Hayakawa F; Miyata Y; Yasuda T; Minami Y; Tsuzuki S; Abe A; Naoe T
Oncogene; 2011 Apr; 30(15):1822-30. PubMed ID: 21217775
[TBL] [Abstract][Full Text] [Related]
2. B Cell Linker Protein (BLNK) Is a Selective Target of Repression by PAX5-PML Protein in the Differentiation Block That Leads to the Development of Acute Lymphoblastic Leukemia.
Imoto N; Hayakawa F; Kurahashi S; Morishita T; Kojima Y; Yasuda T; Sugimoto K; Tsuzuki S; Naoe T; Kiyoi H
J Biol Chem; 2016 Feb; 291(9):4723-31. PubMed ID: 26703467
[TBL] [Abstract][Full Text] [Related]
3. The reduced and altered activities of PAX5 are linked to the protein-protein interaction motif (coiled-coil domain) of the PAX5-PML fusion protein in t(9;15)-associated acute lymphocytic leukemia.
Qiu JJ; Chu H; Lu X; Jiang X; Dong S
Oncogene; 2011 Feb; 30(8):967-77. PubMed ID: 20972455
[TBL] [Abstract][Full Text] [Related]
4. Identification of PML as novel PAX5 fusion partner in childhood acute lymphoblastic leukaemia.
Nebral K; König M; Harder L; Siebert R; Haas OA; Strehl S
Br J Haematol; 2007 Oct; 139(2):269-74. PubMed ID: 17897302
[TBL] [Abstract][Full Text] [Related]
5. Promyelocytic leukemia protein induces arsenic trioxide resistance through regulation of aldehyde dehydrogenase 3 family member A1 in hepatocellular carcinoma.
Zhang X; Yang XR; Sun C; Hu B; Sun YF; Huang XW; Wang Z; He YF; Zeng HY; Qiu SJ; Cao Y; Fan J; Zhou J
Cancer Lett; 2015 Sep; 366(1):112-22. PubMed ID: 26118777
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional regulation is affected by subnuclear targeting of reporter plasmids to PML nuclear bodies.
Block GJ; Eskiw CH; Dellaire G; Bazett-Jones DP
Mol Cell Biol; 2006 Dec; 26(23):8814-25. PubMed ID: 16966371
[TBL] [Abstract][Full Text] [Related]
7. Paired box gene 5 is a novel tumor suppressor in hepatocellular carcinoma through interaction with p53 signaling pathway.
Liu W; Li X; Chu ES; Go MY; Xu L; Zhao G; Li L; Dai N; Si J; Tao Q; Sung JJ; Yu J
Hepatology; 2011 Mar; 53(3):843-53. PubMed ID: 21319196
[TBL] [Abstract][Full Text] [Related]
8. AXIN is an essential co-activator for the promyelocytic leukemia protein in p53 activation.
Li Q; He Y; Wei L; Wu X; Wu D; Lin S; Wang Z; Ye Z; Lin SC
Oncogene; 2011 Mar; 30(10):1194-204. PubMed ID: 21057547
[TBL] [Abstract][Full Text] [Related]
9. Functional heterogeneity of PAX5 chimeras reveals insight for leukemia development.
Fortschegger K; Anderl S; Denk D; Strehl S
Mol Cancer Res; 2014 Apr; 12(4):595-606. PubMed ID: 24435167
[TBL] [Abstract][Full Text] [Related]
10. PML control of cytokine signaling.
Maarifi G; Chelbi-Alix MK; Nisole S
Cytokine Growth Factor Rev; 2014 Oct; 25(5):551-61. PubMed ID: 24861946
[TBL] [Abstract][Full Text] [Related]
11. A novel PAX5-ELN fusion protein identified in B-cell acute lymphoblastic leukemia acts as a dominant negative on wild-type PAX5.
Bousquet M; Broccardo C; Quelen C; Meggetto F; Kuhlein E; Delsol G; Dastugue N; Brousset P
Blood; 2007 Apr; 109(8):3417-23. PubMed ID: 17179230
[TBL] [Abstract][Full Text] [Related]
12. PML tumor suppressor protein is required for HCV production.
Kuroki M; Ariumi Y; Hijikata M; Ikeda M; Dansako H; Wakita T; Shimotohno K; Kato N
Biochem Biophys Res Commun; 2013 Jan; 430(2):592-7. PubMed ID: 23219818
[TBL] [Abstract][Full Text] [Related]
13. [Promyelocytic leukaemia protein and defect in transforming growth factor-beta signal pathway in acute promyelocytic leukaemia].
Fuchs O; Provazníková D; Peslová G
Cas Lek Cesk; 2005; 144(2):90-4. PubMed ID: 15807293
[TBL] [Abstract][Full Text] [Related]
14. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway.
Lallemand-Breitenbach V; Jeanne M; Benhenda S; Nasr R; Lei M; Peres L; Zhou J; Zhu J; Raught B; de Thé H
Nat Cell Biol; 2008 May; 10(5):547-55. PubMed ID: 18408733
[TBL] [Abstract][Full Text] [Related]
15. Promyelocytic leukemia protein is required for gain of function by mutant p53.
Haupt S; di Agostino S; Mizrahi I; Alsheich-Bartok O; Voorhoeve M; Damalas A; Blandino G; Haupt Y
Cancer Res; 2009 Jun; 69(11):4818-26. PubMed ID: 19487292
[TBL] [Abstract][Full Text] [Related]
16. RXR is an essential component of the oncogenic PML/RARA complex in vivo.
Zhu J; Nasr R; Pérès L; Riaucoux-Lormière F; Honoré N; Berthier C; Kamashev D; Zhou J; Vitoux D; Lavau C; de Thé H
Cancer Cell; 2007 Jul; 12(1):23-35. PubMed ID: 17613434
[TBL] [Abstract][Full Text] [Related]
17. Regulation of apoptosis by PML and the PML-NBs.
Bernardi R; Papa A; Pandolfi PP
Oncogene; 2008 Oct; 27(48):6299-312. PubMed ID: 18931695
[TBL] [Abstract][Full Text] [Related]
18. PML positively regulates interferon gamma signaling.
El Bougrini J; Dianoux L; Chelbi-Alix MK
Biochimie; 2011 Mar; 93(3):389-98. PubMed ID: 21115099
[TBL] [Abstract][Full Text] [Related]
19. β-catenin inhibits promyelocytic leukemia protein tumor suppressor function in colorectal cancer cells.
Satow R; Shitashige M; Jigami T; Fukami K; Honda K; Kitabayashi I; Yamada T
Gastroenterology; 2012 Mar; 142(3):572-81. PubMed ID: 22155184
[TBL] [Abstract][Full Text] [Related]
20. Knocking down PML impairs p53 signaling transduction pathway and suppresses irradiation induced apoptosis in breast carcinoma cell MCF-7.
Bao-Lei T; Zhu-Zhong M; Yi S; Jun-Jie Q; Yan D; Hua L; Bin L; Guo-Wei Z; Zhi-Xian S
J Cell Biochem; 2006 Feb; 97(3):561-71. PubMed ID: 16215989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
